Skip to main content

Advertisement

SpringerLink
Log in

A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

This multicenter, randomized trial assessed the efficacy and safety of a recombinant human thrombopoietin (rhTPO) in patients with persistent primary immune thrombocytopenia (ITP) who had failed glucocorticosteroid treatment. A total of 140 eligible patients were randomized to receive rhTPO + danazol (rhTPO group, 73 patients) or danazol (control group, 67 patients) alone. During the first phase, the increase in the mean maximal platelet counts (101.2 × 109/L) and the area under curve (749.6) in the rhTPO group were significantly higher compared to control (33.3 × 109/L and 316.2; P = 0.0060 and 0.0000, respectively). The major response rate (MRR) and total response rate (TRR) in the rhTPO group were 38.4 and 60.3 %, respectively, significantly higher than in control (MRR 7.9 %, P = 0.0003; TRR 36.5 %, P = 0.0104). In the control group, 45 patients with platelet counts <20 × 109/L were given rhTPO during the second phase and achieved MRR 31.1 % and TRR 66.7 %. The mean platelet counts in the rhTPO group were still approximately 50 × 109/L on day 28 of the study. The overall incidence of rhTPO-related adverse events was 13.6 %. All the adverse events were generally mild. This study demonstrated that rhTPO was well tolerated, and it markedly increased platelet counts in chronic ITP patients. Stimulation of platelet production by rhTPO may provide a new therapeutic option for patients with ITP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rodeghiero F, Ruggeri M. Chronic immune thrombocytopenic purpura. New agents. Hamostaseologie. 2009;29:76–9.

    PubMed  CAS  Google Scholar 

  2. Kuter DJ. Future directions with platelet growth factors. Semin Hematol. 2000;37:41–9.

    Article  PubMed  CAS  Google Scholar 

  3. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887–95.

    Article  PubMed  CAS  Google Scholar 

  4. Cremer M, Schulze H, Linthorst G, Folman CC, Wehnert S, Strauss G, et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. Ann Hematol. 1999;78:401–7.

    Article  PubMed  CAS  Google Scholar 

  5. Hou M, Ji CY, Zhu YY, Xu CG, Zhang MH. Serum thrombopoietin level in patients with thrombocytopenia. Chin J Med. 1999;79:356–7.

    Google Scholar 

  6. Liao XM, Deng CQ, Niu T, Meng WT, Zhang J, Wang Y. Study of thrombopoietin and chronic idiopathic thrombocytopenia purpura. Chin J Hematol. 2001;22:473–5.

    CAS  Google Scholar 

  7. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533–8.

    Article  PubMed  Google Scholar 

  8. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565–8.

    Article  PubMed  CAS  Google Scholar 

  9. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568–71.

    Article  PubMed  CAS  Google Scholar 

  10. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571–4.

    Article  PubMed  CAS  Google Scholar 

  11. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94:365–7.

    PubMed  CAS  Google Scholar 

  12. von dem Borne A, Folman C, van den Oudenrijn S, Linthorst G, de Jong S, de Haas M. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Blood Rev. 2002;16:57–9.

    Article  Google Scholar 

  13. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628–38.

    Article  PubMed  CAS  Google Scholar 

  14. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.

    Article  PubMed  CAS  Google Scholar 

  15. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85–93.

    Article  PubMed  CAS  Google Scholar 

  16. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641–8.

    Article  PubMed  CAS  Google Scholar 

  17. Zhao YQ, Wang QY, Zhai M, Xu J, Chen XQ, Liu WL, et al. A multicenter clinical study of rhTPO treatment in chronic refractory idiopathic thrombocytopenia purpura. Chin J Intern Med. 2004;43:608–10.

    Google Scholar 

  18. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–8.

    Article  PubMed  CAS  Google Scholar 

  19. Basser RL, O’Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599–602.

    Article  PubMed  CAS  Google Scholar 

  20. Hua BL, Zhao YQ, Wang SJ, Zhu TN, Zhao YQ. Development of recombinant human thrombopoietin antibodies following multi-dosing, subcutaneously medication in thrombocytopenic patients. Chin J Thromb Hemostasis. 2005;2:59–61.

    Google Scholar 

  21. Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol. 2008;69(Suppl):9–18.

    Google Scholar 

  22. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68:901–12.

    Article  PubMed  CAS  Google Scholar 

  23. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109:4607–16.

    Article  PubMed  CAS  Google Scholar 

  24. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.

    Article  PubMed  CAS  Google Scholar 

  25. Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics. 2010;4:139–45.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was partially supported by Special Research Projects 200802031 (to Renchi Yang), Ministry of Health People’s Republic of China.

Conflict of interest

All the authors declare no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China

    Shujie Wang & Yongqiang Zhao

  2. Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Renchi Yang

  3. Affiliated Union Hospital of Huazhong University of Science and Technology, Wuhan, China

    Ping Zou

  4. Qilu Hospital of Shandong University, Jinan, China

    Ming Hou

  5. The First Affiliated Hospital of Suzhou University, Suzhou, China

    Depei Wu

  6. Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    Zhixiang Shen

  7. Institute of Hematology, Peking University People’s Hospital, Beijing, China

    Xijing Lu

  8. The First Affiliated Hospital, China Medical University, Shenyang, China

    Yan Li

  9. Xijing Hospital, Fourth Military Medical University, Xi’an, China

    Xiequn Chen

  10. West China Hospital, Sichuan University, Chengdu, China

    Ting Niu

  11. The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China

    Hui Sun

  12. General Hospital of Chinese People’s Liberation Army, Beijing, China

    Li Yu

  13. Beijing Friendship Hospital, Capital Medical University, Beijing, China

    Zhao Wang

  14. Henan Province People’s Hospital, Zhengzhou, China

    Yin Zhang

  15. Beijing Hospital, The Ministry of Health, Beijing, China

    Naibai Chang

  16. Beijing DMS Pharma Ltd., Beijing, China

    Gaokui Zhang

Authors
  1. Shujie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renchi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhixiang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xijing Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiequn Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ting Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hui Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Li Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Zhao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Naibai Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Gaokui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yongqiang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yongqiang Zhao.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 41 kb)

About this article

Cite this article

Wang, S., Yang, R., Zou, P. et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol 96, 222–228 (2012). https://doi.org/10.1007/s12185-012-1124-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1124-8

Keywords

Search

Navigation